let's join forces

Why STI Pharma

STI offers an expanding presence in the injectable market. Our management team has experience in product launch, sales, marketing, and distribution. The company has differentiated, strong C-level relationships with key GPOs and IDNs. Our partners benefit from our wholesale, hospital, retail and government experience and relationships. At STI we strive to maintain a reputation for quality, compliance and customer service.

 

We are currently focused on:

Its all about the Experience

Expertise and Market Access

We are committed to providing our partners with exceptional service.

  • Frank Mullery joined STI Pharma in the Fall of 2019 as President and Chief Commercial Officer
  • Frank brings over 15 years of experience in the pharmaceutical industry and was most recently at Mylan where he led the Institutional business and helped establish the company as a key player in the injectables market
  • Frank has launched over 40 injectable products, including complex products and Biosimilars. He also has established key parnterships with GPO's, IDN's and wholesale partners.
  • A team with previous experience launching over 40 injectables, with vast majority securing market leadership positions
  • Surgical strategies for each product developed by deep understanding of relationships between GPO’s, IDN’s, and Hospital members
  • Experience establishing unique contracting relationships with key customers, including value incentive, portfolio, and launch programs.
  • C-level relationships across nation’s top Institutional customers providing UNPRECEDENTED ACCESS
  • Unique contracting programs provide immediate VALUE CREATION
  • Creative alliances which have led to becoming PARTNER OF CHOICE

Know your market

Injectable Market

U.S. Generic Injectables Market Growth

Market Trends

  • The U.S. Generic Injectables market is expected to grow 7.5%, reaching $18bn by 2024
    • Oncology represents the largest therapeutics area, accounting for 36% of the U.S. Generic Injectables market in 2016
  • Injectable drugs are administered mainly in hospitals and clinics and sold to these organizations through contracts of GPOs
    • 86% of generic injectables are being sold through the hospital
  • Limited competition and market penetration / high growth opportunities
  • Select opportunities also exist due to increasing shortages due to manufacturing complexity and strict requirements for quality, sterility and logistics of injectable drugs compared to other solid or liquid dosage forms
  • We've got you covered

    Sales and Marketing

    STI Sales and Marketing is made up of a team of seasoned industry professionals. Our expertise broadly includes sales of Branded, Generic, and OTC products with expertise in new product launches, sales management systems and analytics, distribution, operations and contracting.

    Key Takeaways

    Partnership Summary

    1

    STI Pharma leverages deep institutional market experience to optimize product performance

     

    2

    Team with proven track record of success launching over 40 injectable products including biosimilars and complex formulations

     

    3

    Partner of choice with GPO’s, IDN’s, and Hospitals with top to top relationships

     

    4

    Strategic sales force provides surgical launches with thorough understanding of value chain and GPO – Member relationships

     

    5

    Unique contracting agreements drive market share

     

    6

    Focused on growth through continued partner relationships

     

    find us here

    Partners

    View As Text List